Company intelligence / Profile preview

Kin

Ownership: Private
Development stage: Commercial

Overview

Kinvard Bio, a spin-out from Harvard University's Myers Lab, develops oxepanoprolinamides—a novel class of ribosome-targeting antibiotics with broad-spectrum activity against Gram-positive and Gram-negative bacteria. Their lead programs are in lead optimization targeting severe hospital and community infections, including drug-resistant pathogens. The company’s compounds have demonstrated preclinical efficacy against challenging superbugs.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Harvard University/Myers Lab

Beyond the preview

Go deeper on Kin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kin.

Explore the full profile